Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Scores March M&A Double Whammy With NxThera

Executive Summary

In its second acquisition deal this month, Boston Scientific has agreed to pay up to $406m for NxThera, maker of the Rezῡm system for treating benign prostatic hyperplasia.

You may also be interested in...



Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018

Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.

M&A Analysis – Deals March On In Big Month For Boston Scientific

Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT122381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel